Cardinal Health posted a fourth-quarter EPS of $2.91, significantly exceeding the $2.44 consensus estimate. For investors, this robust performance highlights the company's operational strength and effective strategic execution.
Key Highlights
- Fourth-quarter Revenue reached $63.7 billion, a 6% increase year-over-year.
- Cardinal Health's fiscal year 2027 non-GAAP EPS guidance suggests growth of 13% to 15%.
- Diluted EPS of $2.91 beat the consensus estimate of $2.44, highlighting strong profitability.
- Fourth‑quarter revenue reached $63.7 billion, a 6% year‑over‑year increase driven by a 15% rise in the Pharmaceutical and Specialty Solutions segment.
Cardinal Health (NYSE: CAH) announced a strong fourth-quarter fiscal year 2026 performance, reporting a Diluted Earnings per Share (EPS) of $2.91, which surpassed the consensus estimate of $2.44. This marks a notable increase as the healthcare distributor capitalized on effective operational strategies and growing Demand across its segments. The quarterly revenue hit $63.7 billion, reflecting a 6% annual growth.
This solid performance reinforces investor confidence amid a market Capitalization of approximately $55.4 billion, with shares rising 16.8% year-to-date and 2.8% in the past month.
Significant Quarterly Increase
Revenues for the fourth quarter increased by 6% compared to the same period last year, reaching $63.7 billion. This growth was partially driven by a strong 15% rise in revenue from Cardinal Health’s Pharmaceutical and Specialty Solutions segment. Typically, fluctuations in peer performance, evidenced by a slight decline in sector counterparts such as COR and MCK, highlight Cardinal Health's strong positioning within the market.
While competitors faced challenges, Cardinal Health leveraged strategic relationships and operational efficiencies to achieve this growth, underscoring its market resilience.
Earnings Mechanics
Cardinal Health reported a remarkable 70% increase in fourth-quarter GAAP operating earnings, totaling $729 million. Its non-GAAP diluted EPS rose 40% to $2.91, mainly due to the recognition of a one-time benefit from IEEPA Tariff refunds amounting to $100 million. The results reflected a comprehensive improvement across all operational segments, with adjusted free Cash Flow hitting $5 billion for the year.
Contextually, the company’s effective tax rate also decreased, which benefitted its profitability metrics. These financial improvements indicate solid management execution and provide a favorable foundation for future performance.
Positive Momentum for Fiscal 2027
Looking ahead, Cardinal Health issued optimistic guidance for fiscal year 2027, projecting non-GAAP EPS growth between 13% and 15%, translating to an expected range of $12.40 to $12.60. The forecast reflects confidence in operational execution, buoyed by recent acquisitions that enhance its market capabilities. With a strong Operating Cash Flow of $5.2 billion, the company is also poised for continued investments in growth initiatives.
The imminent Earnings Call on August 11 will provide additional insights into strategic direction and operational updates that could further impact investor sentiment.
Peers Moving on This News
- Cencora Inc (NYSE: COR) down 0.5%
- McKesson Corp (NYSE: MCK) down 0.3%






Please wait processing your request...